A lower total incidence of drug-related treatment-emergent adverse events (TEAEs) was reported for patients in the insulin glargine group, compared with the NPH insulin group;the most common drug-related TEAEs were hypoglycaemia (33.6% versus 40.7%) and weight gain (0.9% versus 1.9%). This evidence concerns the gene INS and Hypoglycemia.